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Summary
Tumors develop through successive stages characterized by changes in gene expression and protein function. Gene
expression profiling of pancreatic islet tumors in a mouse model of cancer revealed upregulation of cathepsin cysteine
proteases. Cathepsin activity was assessed using chemical probes allowing biochemical and in vivo imaging, revealing
increased activity associated with the angiogenic vasculature and invasive fronts of carcinomas, and differential expression
in immune, endothelial, and cancer cells. A broad-spectrum cysteine cathepsin inhibitor was used to pharmacologically
knock out cathepsin function at different stages of tumorigenesis, impairing angiogenic switching in progenitor lesions,
as well as tumor growth, vascularity, and invasiveness. Cysteine cathepsins are also upregulated during HPV16-induced
cervical carcinogenesis, further encouraging consideration of this protease family as a therapeutic target in human cancers.
Introduction of which a subset (25%) subsequently acquire the ability to
switch on angiogenesis (Folkman et al., 1989). A subset of these
angiogenic islets (15%–20%) develop into tumors; both benign,Cancer is a complex set of proliferative diseases that are thought
encapsulated lesions and invasive carcinomas (Lopez andto arise in most cases via multistep pathways involving an accu-
Hanahan, 2002). This multistage pathway suggests the sequen-mulation of genetic and epigenetic changes, including inactiva-
tial involvement of multiple rate-limiting genetic and epigenetiction of tumor suppressor genes and activation of oncogenes
events in the progression from normal cells to tumors.(Hanahan and Weinberg, 2000; Kinzler and Vogelstein, 1996).
To define novel molecular pathways to cancer, we soughtThe development of tumors can be separated into a series
to profile changes in gene expression in each of the lesionalof distinct clinical, histological, and temporal stages. Mouse
stages of sequential tumor development in RIP1-Tag2 mice.models of multistage carcinogenesis allow the study of the mo-
We present evidence that a subset of papain family Clan CA
lecular basis of this process, and the identification and charac-
cysteine proteases known as cathepsins make an important
terization of molecular effectors of cancer in many organs (Wu contribution to the development of islet tumors. The traditional
and Pandolfi, 2001). term “cathepsin” includes serine, cysteine, and aspartyl type
RIP1-Tag2 transgenic mice develop multiple pancreatic islet proteases. The work presented here focuses on the cysteine
tumors by 12–14 weeks of age, as a consequence of expressing cathepsin family, which comprises 11 human members to date
the SV40 T antigen (Tag) oncogenes in insulin-producing  cells (cathepsins B, C, H, F, K, L, O, S, V, W, and X/Z) (Turk et al.,
(Hanahan, 1985). Tumor development in these mice proceeds 2002), and will be collectively abbreviated hereafter simply as
through a series of discrete stages, in which approximately 50% cathepsins. These cathepsins are primarily intracellular prote-
ases that function in terminal protein degradation in lysosomesof the 400 islets in the pancreas become hyperproliferative,
S I G N I F I C A N C E
The use of chemical tools to evaluate biological systems is affording powerful means to investigate cellular processes, signaling
networks, and molecular mechanisms. In this study, activity-based probes and a class-specific small molecule inhibitor were used
to investigate the functional importance of the cathepsin cysteine proteases in cancer. Imaging of cysteine cathepsin activity in vivo
revealed pronounced upregulation in precursor and neoplastic lesions of the endocrine pancreas and uterine cervix in two mouse
models of multistage cancer, with activity localized to the angiogenic vasculature and invasive fronts of tumors. Correspondingly,
pharmacological inhibition of cysteine cathepsin activity impaired angiogenic switching, tumor growth, and invasion in the pancreatic
model. The results collectively motivate therapeutic investigation of cysteine cathepsin inhibitors in human cancers.
CANCER CELL : MAY 2004 · VOL. 5 · COPYRIGHT  2004 CELL PRESS 443
A R T I C L E
(Turk et al., 2001) and protein processing in other intracellular progressive increase in overall levels of cathepsin activity during
organelles (e.g., hormone secretory granules [Yasothornsrikul RIP1-Tag2 tumorigenesis (Figure 1C). Individual bands from
et al., 2003]). However, cathepsins have specific roles in physio- whole tumor lysates were resolved by 1D gel electrophoresis
logical processes, including bone remodeling, epidermal ho- (data not shown), and identified by single-step purification using
meostasis, and antigen presentation (reviewed in Turk et al., the biotin tag, followed by mass spectrometry-based sequenc-
2002). Enzymes of this group can be found at the cell surface, ing. Cathepsins B, C, L, and Z (Figure 1C) were identified by
both in T cells (Balaji et al., 2002) and in certain tumors (reviewed their sequence, and their identities confirmed by immunoprecip-
in Roshy et al., 2003), and in some cases are secreted (Brix et itation experiments with antibodies recognizing individual ca-
al., 2001; Koblinski et al., 2002; Mort et al., 1985; Recklies et thepsins (data not shown). The specificity of the ABP was con-
al., 1985). Surveys of human tumors have suggested an associa- firmed by competition experiments using a broad-spectrum
tion of certain cathepsins with malignancy (Lah and Kos, 1998; cathepsin cysteine protease inhibitor, JPM-OEt (Meara and
Rao, 2003; Yan et al., 1998), but this class of proteases has Rich, 1996) (Figure 1B), and a cathepsin B-specific inhibitor,
not been a prominent target for anticancer therapies, in contrast MB-074 (Bogyo et al., 1999). Preincubation of tumor lysates with
to the matrix metalloproteases. We show here using small mole- JPM-OEt completely abolished DCG-04 labeling of all active
cule inhibitors and activity based probes that cathepsin activity cathepsins in the 20–40 kDa range (lane 2, Figure 1D). Likewise,
is increased during tumorigenesis and that inhibition of cathep- pretreatment with MB-074 specifically blocked cathepsin B ac-
sin function impairs tumor development. tivity (lane 3, Figure 1D; note the absence of the cathepsin B
band, as indicated by the asterisk), but not other cathepsins.
Results Heat-inactivated controls also showed that all labeled proteins
were in fact proteases (data not shown). We did not detect
Cathepsins are upregulated during active cathepsins H or S by mass spectrometric sequencing of
RIP1-Tag2 tumorigenesis proteins purified from whole tumor lysates with DCG-04, which
RIP1-Tag2 transgenic mice develop tumors over time through may reflect much lower expression in the case of cathepsin H.
a series of highly reproducible stages (Hanahan, 1985). To ex- However, cathepsin S is expressed at higher levels, both in the
amine the gene expression changes associated with progres- whole tumors and in sorted inflammatory cells, and yet it was
sion through each stage, we performed an Affymetrix microarray not detected as an active enzyme in whole tumor lysates. This
profiling experiment on cDNA from pools of normal (nontrans- discrepancy could be attributed to posttranscriptional regula-
genic) islets, hyperplastic islets, angiogenic islets, and tumors
tion such that mRNA but not active protease was produced;
using the 11K and 19K mouse chips (Affymetrix). Following
however, we suspect that the activity probe may bind preferen-
scaling of the hybridization signals for each of the four distinct
tially to other cathepsins in the complex tumor lysate. Indeed,
stages, data sets were grouped using a self-organizing mapping
when the constituent cells were first separated from the whole
algorithm (SOM) (Tamayo et al., 1999) into clusters of genes
tumors and lysates labeled with the biotinylated ABP, a bandshowing similar expression patterns (our unpublished data).
corresponding to the molecular weight of active cathepsin SSeveral cathepsins were found in a SOM cluster that grouped
was detected in the infiltrating immune cells (see Figure 3A,genes whose expression was low in normal, hyperplastic, and
band labeled I*). Ongoing analyses are expected to addressangiogenic islets, and markedly increased in tumors (Figure 1A).
this possible explanation.Cathepsins H and L were only detectably expressed in tumors,
We next used an ABP to label active proteases in vivo. Awhereas cathepsins C and Z were expressed at much higher
cell-permeable fluorescent analog of DCG-04 incorporating thelevels than in the precursor stages. Two other cathepsins, B
BODIPY fluorophore as a tag, BODIPY 530/550-DCG-04and S, were grouped in another cluster that showed a more
(Greenbaum et al., 2002) (Figure 1B), was injected intravenouslygradual upregulation during tumorigenesis (Figure 1A). Real-
into RIP1-Tag2 mice at different stages of tumor developmenttime, quantitative RT-PCR using primer pairs specific for the
(Figure 2). There was little or no cathepsin activity detected bysix cathepsin mRNAs was used to evaluate expression in inde-
the ABP in normal islets (Figures 2A and 2B), nor in the sur-pendently isolated pools of normal islets, angiogenic islets, and
rounding normal exocrine pancreas, suggesting that the cathep-tumors. The expression patterns of the six cathepsins in these
sins expressed in normal lysosomes and secretory granulesdistinctive stages were similar to those observed in microarray
were either inaccessible to the probe or present at levels belowanalysis, again indicating upregulation in tumors (our unpub-
the threshold of detection. In contrast, cathepsin activity waslished data).
clearly evident in angiogenic islets (Figures 2C and 2D) andTo determine if the enzymatic activity of these proteases was
tumors (Figures 2E and 2F). The cellular localization of cathepsinsimilarly upregulated during tumorigenesis, we used chemical
activity was further resolved by confocal microscopy, as shownprobes specific for this family of cysteine cathepsins (Green-
in Figures 2I–2K. Labeled cells within the neoplastic lesionsbaum et al., 2000). These activity-based probes (ABPs) are
showed either a punctate perinuclear signal (Figures 2I andbased on a small molecule scaffold that binds covalently in the
2J, arrows) or a diffuse activity localization, suggestive of cellactive sites of members of the cysteine cathepsin family, thereby
membrane-associated activity, and perhaps of cathepsins se-allowing their specific identification within cell or tissue lysates.
creted into the extracellular microenvironment (Figures 2I andFurthermore, since the probes bind irreversibly to target prote-
2K, arrowheads). We are in the process of further defining theases in an activity-dependent manner, covalent labeling can be
subcellular activity colocalization using cell surface and lyso-used as a direct readout of protease activity levels. Using a
biotinylated ABP called DCG-04 (Figure 1B), we detected a somal markers. Interestingly, there was a clear increase in ca-
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Figure 1. Expression and activity profiling reveals
upregulation of a subset of lysosomal cysteine
proteases
A: Normalized gene expression values for six ca-
thepsin cysteine proteases from Affymetrix mi-
croarrays. Expression values were clustered by
self-organizing mapping (SOM), and the first four
genes fell into the group (SOM cluster) in which
expression was markedly upregulated in tumors
compared to the normal case and the premalig-
nant stages. Two of the other cathepsins (ca-
thepsin B and S) represented on the microarray
showed a more progressive upregulation. N rep-
resents normal islets, H represents hyperplastic
islets, A represents angiogenic (dysplastic) islets,
and T represents tumors.
B: Molecular structures of small-molecule activity
based probes (ABPs) and inhibitors used in this
study.
C: Cathepsin activity profiles for progressive
stages of RIP1-Tag2 tumor development using
the DCG-04 ABP on tissue lysates, controlled for
equal loading. Active cathepsin bands positively
identified by mass spectrometry sequencing are
labeled. Molecular weight markers are indicated
on the side panel.
D: Competition experiments on tumor lysates
demonstrating specificity of the DCG-04 probe.
Incubation of equally loaded tumor lysates with
a broad-spectrum inhibitor, JPM-OEt, abolishes
activity in the 30–40 kDa range (lane 2), whereas
incubation with MB-074, a cathepsin B-specific
inhibitor, abolishes cathepsin B activity as indi-
cated by an asterisk (lane 3).
thepsin activity at the invasive edges of the islet carcinomas vealed by differential mobility of the probe-labeled proteases
by polyacrylamide gel electrophoresis (PAGE). We then used(Figures 2G and 2H), suggestive of a role in tumor invasion.
quantitative RT-PCR to identify the individual cathepsin genes
expressed in each flow-sorted cell population, as shown in Fig-Cell type-specific localization of cysteine
ure 3B. All six cathepsins were expressed in the infiltrating im-cathepsin activity
mune cell fraction, with cathepsins B, C, H, and S being differen-As the islet tumors are comprised of multiple cell types, we
tially abundant compared to the other cell types. By contrast,sought to identify the cell type(s) responsible for providing ca-
the tumor cell fraction preferentially expressed the cathepsinthepsin protease activity. Flow cytometry was used to sort the
L gene. Two points should be considered when evaluating thesolid tumors into three constituent cell types (endothelial, innate
relative activity and gene expression profiles in the sorted cellimmune, and tumor) as previously described (Bergers et al.,
types. First, the endothelial and immune cells represent only2003), and ABP profiling of lysates from the purified cell popula-
2%–5% of the total cells inside the tumors, with the overt onco-tions was performed using the DCG-04 probe. The labeling of
gene transformed cells constituting the majority (90%–95%),equally loaded samples, consisting of lysates from cell types
such that the aggregate contribution of protease activity fromisolated and purified by flow cytometry, reveals infiltrating innate
immune cells to be a significant source of cathepsin activity the overt tumor cells could be comparable to the apparently
higher levels in infiltrating immune cells. Second, the in vivo ABP(Figure 3A). Interestingly, the three constituent cell fractions
apparently have distinctive cathepsin activity profiles, as re- revealed a focal distribution of high-level activity, particularly
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Figure 3. Cell-specific profiles of cathepsin activity and expression in RIP-Tag
tumors
A: Different tumor constituent cell types have distinguishing cathepsin activ-
ity profiles. RIP1-Tag2 tumors were separated into three constituent cell types
by flow cytometry (endothelial [EC], infiltrating immune [IC], and tumor cell
[TC] populations), and the cell lysates incubated with DCG-04. The panel
on the left corresponds to the activity profile in the presorted whole tumor
lysates. Arrows next to the right hand panel indicate cathepsin activities of
different molecular weight unique to immune cells (I) and highlight bands
differing between tumor (T) and endothelial cells (E). All samples are con-
trolled for equal protein loading.
B: Different constituent cell types in tumors have distinct cathepsin expres-
sion profiles. Real-time quantitative RT-PCR of the six cathepsin cysteine
proteases, normalized to a mouse housekeeping gene, mGus, was per-
formed on the mRNA of purified cell types isolated from whole tumors by
FACS. The highest relative levels of expression were detected in the infiltrat-
ing immune cell compartment, with the exception of cathepsin L, which
was most abundant in the tumor cell fraction.
Figure 2. In vivo profiling of cathepsin activity during RIP-Tag tumorigenesis
A–H: Visualization of BODIPY 530/550-tagged DCG-04 in representative im-
ages following intravenous injection in RIP1-Tag2 mice. A and B show the
by each cell type could in principle be playing distinct roles inDCG-04 signal and the corresponding DAPI/DCG-04 merged image in nor-
tumorigenesis.mal islets, C and D in angiogenic islets, E and F in tumors, and G and H in
invasive tumor fronts. Normal islets and lesions are outlined by the white
dotted lines, and surrounded by the normal exocrine pancreas. The scale Inhibition of cathepsin activity affects multiple
bar corresponds to 50 M in A–F and 10 M in G–H.
stages of tumorigenesisI–K: A subset of cells within RIP1-Tag2 tumors are positive for cathepsin
In order to ascertain whether the observed upregulation of ca-activity, as shown in I through K. Punctate staining is indicated by arrows,
with arrowheads highlighting diffuse staining. The scale bar corresponds to thepsin expression and activity was important for RIP1-Tag2
10 M in I and J. tumorigenesis, we used a small molecule inhibitor to block pro-
tease activity. The E-64d analog JPM-565 (Bogyo et al., 1999;
Meara and Rich, 1996; Shi et al., 1992) is a broad-spectrum
irreversible inhibitor for the cysteine cathepsin family. The ester
associated with the angiogenic vasculature and invasive fronts analog of JPM-565, where the free carboxylic acid has been
of carcinomas. These analyses therefore reveal all three cell replaced with an ethyl ester (termed JPM-OEt), is a cell-perme-
types to be suppliers of cathepsin activity, but with different able analog of JPM-565 (Bogyo et al., 1999) (Figure 1B). This
compound was chosen for inhibitor trials due to the increasedbiases amongst the six genes; as such, cathepsins produced
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likelihood that it would be able to access intracellular as well
as extracellular cathepsin targets. RIP1-Tag2 mice were treated
with JPM-OEt in three distinctive trial designs that target differ-
ent stages in tumorigenesis (Bergers et al., 1999). In a 5.5 week
prevention trial, designed to assess the effects of a test agent
on initial angiogenic switching in the normal vasculature of hy-
perplastic progenitor lesions, daily injection of JPM-OEt pro-
duced a 49% reduction in the number of angiogenic islets evi-
dent at a defined endpoint (10.5 weeks of age), when solid
tumors are just forming (Figure 4A) (JPM-OEt, n  14, and
controls, n  20; p  0.0001). In an intervention trial, designed
to interfere with the dramatic growth of nascent solid tumors,
JPM-OEt reduced cumulative tumor volume by 67% at 14.5
weeks of age, relative to littermate, sham-treated controls (Fig-
ure 4B; n  19, JPM-OEt-treated; n  8, n  16, 11-week
and 14.5-week controls respectively; p  0.0001). Finally, in a
regression trial, designed to test the ability of inhibitors to stabi-
lize or regress large tumors and modestly extend lifespan to
a defined endpoint 4 weeks later, JPM-OEt produced “stable
disease,” in that the tumor volume at the endpoint was compara-
ble to that in mice at the 12-week-old starting point of the trial
(Figure 4B). Untreated RIP1-Tag2 mice die at 13–15 weeks of
age; hence there were no age-matched controls for the JPM-
OEt mice treated for 4 weeks to the defined endpoint. Therefore,
we compared the tumor volumes in 14.5-week-old controls with
16-week-old JPM-OEt-treated mice, revealing a 63% reduction
(p  0.0001).
To confirm that the effects of JPM-OEt could be specifically
attributed to inhibition of cysteine cathepsins, we used the cys-
teine cathepsin-specific ABPs to assess the inhibition of cathep-
Figure 4. Inhibition of cathepsin activity affects multiple stages of RIP1-Tag2
sin activity in tumors of mice treated with JPM-OEt; treated tumor development
tumors were analyzed both by ex vivo and in vivo labeling, as
A: Inhibition of cathepsin activity by JPM-OEt significantly decreases the
shown in Figures 4C–4E. Tumor lysates from mice treated with number of angiogenic islets (by 49%) in RIP1-Tag2 10.5-week-old mice (n 
JPM-OEt (collected six hours after the final injection of JPM-OEt) 20 controls, n 14 JPM treated, ***p 0.0001). The means SEM (Wilcoxon
test) are indicated.versus control littermate tumors showed a marked reduction
B: Inhibition of cathepsin activity significantly reduces tumor burden in RIP1-in cathepsin activity (Figure 4C, 70%–80%, using NIH Image
Tag2 mice (n  8, n  8, n  19, for 11-week, 12-week, and 14.5-week RIP1-
software) as measured by residual labeling with the DCG-04 Tag2 controls, respectively. n  16, and n  14 for JPM-OEt-treated 14.5-
probe. Similarly, cathepsin activity in vivo was also dramatically and 16-week-old mice). The tumor burden in 14.5-week JPM-OEt treated
mice is reduced by 67% compared to age-matched untreated controlsreduced, as shown for representative images in Figures 4D and
(***p  0.0001). There are no age-matched control comparisons for the 16-4E in which RIP1-Tag2 mice treated with JPM-OEt (Figure 4D)
week JPM-OEt treated mice, and thus the comparison was made to 14.5-are compared to control littermates (Figure 4E) injected under
week controls, which was statistically significant (***p  0.0001, 63% reduc-
identical conditions with the fluorescent DCG-04 probe. It is tion). The means  SEM (Wilcoxon test) are indicated.
notable that the daily inoculation of mice with JPM-OEt had no C: Cathepsin activity is diminished following treatment of RIP1-Tag2 mice
with a broad-spectrum cathepsin inhibitor, JPM-OEt. Tumor lysates fromdiscernable toxic side effects, even after treating mice for 5.5
multiple JPM-OEt-treated animals and controls were incubated with DCG-weeks. Thus, we observed a clear therapeutic window, in that all
04 in vitro, and gel analysis on equally loaded samples indicates a significant
three experimental therapeutic trials demonstrated anti-tumor decrease in residual cathepsin activity in tumor lysates (70%–80% reduction
efficacy without evident toxicity. as assessed by NIH Image software).
D–E: Cathepsin activity in vivo revealed by the fluorescent ABP is also greatly
reduced following JPM-OEt treatment. D shows the inhibition of cathepsinCathepsin activity contributes to angiogenic switching,
activity by JPM-OEt as compared to untreated control littermates (E). Scaletumor vascularity, and proliferation
bar: 50 M.
We then investigated the mechanism responsible for the sub-
stantive reduction in both angiogenic switching and tumor vol-
ume in JPM-treated mice. The vascularity in angiogenic islets
and tumors was assessed by perfusion of a fluorescent-labeled indistinguishable, indicative of alternative pathways to the same
lectin through the circulatory system. JPM-OEt-treated angio- angiogenic premalignant state. In contrast, many of the JPM-
genic islets did not show any obvious differences in vasculariza- OEt-treated tumors showed a pronounced reduction in vessel
tion, as visualized by the FITC-lectin, compared to control 10.5- density, particularly in the core of larger tumors (Figure 5D), as
week angiogenic lesions (Figures 5A and 5B). Thus, much like compared to the highly vascularized control tumors (Figure 5C).
analogous studies with an MMP inhibitor and MMP-9 gene We confirmed the reductions in vascularity by immunostaining
knockout mice (Bergers et al., 2000), fewer hyperplastic islet with two endothelial-selective antibodies, CD31 and MECA32,
and observed similar results (data not shown). The particularprogenitors switched on angiogenesis, but those that did were
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Figure 5. Inhibition of cathepsin activity affects tumor vascularization during
RIP1-Tag2 tumorigenesis
A–F: Perfusion of RIP1-Tag2 control (A) and JPM-OEt-treated mice (B) with
FITC-lectin revealed no obvious changes in the vasculature of angiogenic
islets at 10.5 weeks of age. However, there were significant reductions in
vascularity seen in solid tumors, as shown by representative comparisons in
C versus D, in which the tumor core vasculature was particularly affected.
Islets are outlined by dashed white lines, and tumor margins are similarly
indicated, with normal exocrine tissue shown in the top left-hand corners.
Figure 6. Cell proliferation is reduced following cysteine cathepsin inhibitionVascular branching is also affected in JPM-OEt-treated tumors (F) in which
branchpoints (indicated by arrowheads in the control tumor [E]) are greatly A–D: Proliferating cells were detected by BrdU incorporation and represen-
reduced or absent, in representative images. The scale bar corresponds to tative images are shown for 10.5-week control (A), JPM-OEt (B), 14.5-week
50 M in A–D and 25 M in E and F. control (C), and JPM-OEt (D) treated time points. Scale bar: 50 M.
E: Graph showing the relative percentages of proliferating (BrdU positive)
cells in treated versus control mice from the three different JPM-OEt trials.
The reduction in proliferating cells by comparison to the relevant controls
are 52%, 28%, and 39%, respectively, for JPM-OEt-treated 10.5-, 14.5-, anddefect in vascularization of the core, but not the edges of JPM-
16-week-old mice. The means  SEM. (Wilcoxon test) are indicated.OEt-treated tumors, may reflect vessel cooption at the tumor
margins from the surrounding normal, exocrine tissue (Holash
et al., 1999).
The tumor vasculature was also characterized by a reduction
of the effects we attribute to cathepsin activity in pancreaticof vessel branching in JPM-OEt-treated versus untreated tu-
islet tumorigenesis.mors (Figures 5E and 5F), suggesting impairment of endothelial
Tumor cell proliferation, as assessed by BrdU incorporation,basement membrane degradation as a result of inhibiting ca-
was significantly decreased in all stages of RIP1-Tag2 tumori-thepsin activity. It is well established that proteolysis of the
genesis, particularly in the angiogenic islet stage (Figures 6A–basement membrane is a critical step in vessel sprouting during
6D). There was a 52% reduction in cell proliferation in JPM-angiogenesis (Carmeliet, 2003; Kalluri, 2003), and interestingly,
OEt-treated angiogenic islets (p  0.0001), while proliferationcathepsin B has been shown to directly degrade three major
in JPM-OEt-treated tumors was reduced by 28% in 14.5-weekbasement membrane components, laminin, collagen IV, and
mice (I.T.) (p  0.01) and 39% in 16-week mice (R.T.) (p fibronectin, at physiological pH (Buck et al., 1992). It is also
0.001), as compared to 14.5-week controls (Figure 6E). Sincenotable that a recent study of a cathepsin S knockout mouse
the vasculature in the angiogenic islets of JPM-OEt-treated miceimplicated cathepsin S as an enhancer of angiogenesis associ-
was indistinguishable from that of controls (albeit less frequent),ated with wound healing in the skin (Shi et al., 2003), suggesting
that it in particular may be involved in the angiogenic component the reduced proliferation index suggests that JPM-OEt is di-
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rectly interfering with tumor cell growth. Thus we imagine a
direct role for cysteine cathepsins in facilitating proliferation of
the oncogene-expressing  cells, in addition to effecting a ro-
bust tumor vasculature.
In contrast to the effects on cell proliferation, inhibition of
cathepsin activity with JPM-OEt had no discernible impact on
the frequency of apoptosis (data not shown). While certain ca-
thepsins have been shown to be involved in mediating apoptosis
triggered by specific stimuli (e.g., TNF-induced apoptosis
[Foghsgaard et al., 2001]), the pharmacological trials with JPM-
OEt indicate that cathepsins are not centrally involved in the
acquired resistance to apoptosis that is demonstrably important
in this islet tumorigenesis model (Christofori et al., 1994; Naik
et al., 1996).
Cathepsins contribute to the capability
for invasive growth
The in vivo ABP revealed a focal increase in cathepsin activity
at the invasive edges of tumors (Figures 2G and 2H), suggesting
a role in facilitating local tumor invasion. Consistent with this
hypothesis, daily treatment of RIP1-Tag2 mice with JPM-OEt
significantly delayed progression to both widely invasive (IC-2)
and microinvasive (IC-1) carcinomas in both intervention (I.T.)
and regression trials (R.T.) (Figure 7G). Detailed grading of he-
matoxylin and eosin-stained tumors (Lopez and Hanahan, 2002)
showed that mice treated in an intervention trial with JPM-OEt
had no high-grade IC-2 class carcinomas, producing a clear
and significant shift toward more benign, encapsulated tumors
(representative images shown in Figures 7A and 7B). When
starting the treatment regimen later, in a regression trial at 12
weeks (where carcinomas have already formed), JPM-OEt sig-
nificantly reduced but did not abolish the incidence of invasive
tumors of both classes at 16 weeks. Since the epithelial cell-
cell interaction molecule E-cadherin is characteristically down-
regulated upon progression to carcinomas (Perl et al., 1998;
Vleminckx et al., 1991), in particular in the RIP1-Tag2 model,
we used it as an independent criterion for the invasive growth
capability, to complement the grading of H&E stained sections;
to that end, tumors from JPM-OEt-treated and control RIP1-
Tag2 mice were immunostained with antibodies for E-cadherin.
There was a complete concordance with the histological grading
of invasion: we detected no tumors that lacked E-cadherin ex-
pression altogether (IC-2) following an I.T., and saw reduced
Figure 7. Inhibition of cathepsin activity reduces invasive properties of RIP1-frequencies of tumors with uniform or localized downregulation
Tag2 tumors
of E-cadherin (IC-2 and IC-1, respectively) after the R.T. (repre-
A and B: Histological comparison of representative 14.5-week control (A)sentative images shown in Figures 7C–7F). Thus, by both crite- and JPM-OEt-treated (B) tumors. Multiple invasive fronts are frequent in
ria, cathepsin activity is contributing to the invasive growth pro- control tumors as indicated by arrows, whereas the majority of JPM-OEt-
treated tumors (t) remain encapsulated and histologically distinct from thegram, as evidenced by suppression of invasive carcinomas with
surrounding normal exocrine tissue (e). Scale bar: 50 M.the JPM-OEt inhibitor, consistent with the in situ labeling by
C–F: E-cadherin downregulation, diagnostic of the invasive phenotype, isthe ABP of cathepsin activity in invasive regions of the tumors
not evident in JPM-OEt-treated tumors (D and F) as compared to control
(Figures 2G and 2H). tumors (C and E). E-cadherin immunostaining is shown in red (C and D) and
merged with the DAPI counterstain (E and F). t indicates tumor, and e
indicates normal exocrine pancreas. Scale bar: 100 M.Cysteine cathepsin activity is upregulated during tumor
G: Graph showing the relative proportions of encapsulated, microinvasive,development in a mouse model of cervical cancer
and invasive carcinomas in controls versus 14.5-week JPM-OEt, and 16-
To begin addressing the general relevance of the pronounced week JPM-OEt (R.T.) -treated mice, revealing fewer malignant tumors fol-
upregulation in cysteine cathepsin expression and activity ob- lowing JPM-OEt treatment. Comparison of the two time points is indicative
of delayed time to progression to carcinoma, a parameter commonly usedserved in the RIP1-Tag2 model of islet cell carcinogenesis, we
to evaluate responses in human clinical trials.have used the fluorescent ABP to visualize in vivo activity in
another mouse model of human cervical cancer. These trans-
genic mice express the human papillomavirus type 16 onco-
genes under the keratin 14 promoter and develop invasive can-
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localized to the stroma underlying the dysplastic epidermis (Fig-
ure 8C), and was seen throughout the cervical tumors (Figure
8D). Higher magnification of both the dysplastic (Figure 8E) and
cancerous (Figures 8F and 8G) lesions revealed a similar activity
localization to that seen in the lesional pancreas of RIP1-Tag2
mice, associated both with the cell surface of endothelial cells
(Figure 8F) and with punctate perinuclear regions of individual
cells within the tumor (Figure 8G).
Discussion
In this study, activity-based probes and a class-specific small
molecule inhibitor were used to investigate the functional impor-
tance of the cathepsin cysteine proteases in cancer. We found
that several cathepsins were upregulated during tumor progres-
sion and then demonstrated their functional involvement in a
prototypical mouse model of pancreatic islet cell cancer. Of
the eleven known mammalian cysteine cathepsins (Turk et al.,
2002), expression of six mouse cathepsin genes was upregu-
lated during RIP1-Tag2 tumorigenesis. Four of these cathepsins
(B, C, L, and Z) were specifically identified as being substantively
increased in their protease activity in solid tumors. The potential
of reporter substrates to probe protease activity in tumors in vivo
has previously been demonstrated (Bremer et al., 2001; Tung
et al., 2000) using xenografts of human cancer cell lines that
expressed high levels of the candidate proteases. While illustra-
tive, the experimental design did not allow for evaluation of the
endogenous proteases within a tumor or its constituent cell
types. Furthermore, this method does not allow for the biochem-
ical analysis of target proteases contributing to hydrolysis ofFigure 8. In vivo imaging with the activity-based probe reveals cathepsins
are also activated during HPV16-induced cervical carcinogenesis the reporter. We have expanded and refined this approach,
showing herein that ABPs for cathepsin cysteine proteases canRepresentative images are shown following intravenous injection of the
fluorescent ABP (BODIPY530/550-tagged DCG-04) into multiple K14- be used to visualize endogenous protease activity in vivo during
HPV16/E2 and control mice; cervical tissue sections were stained with DAPI the stepwise progression of organ-specific tumorigenesis, and
and visualized by fluorescent microscopy. we demonstrate that the proteases involved can be identifiedA: The cervix in an estrogen-treated FVB/n control mouse did not evidence
and monitored biochemically.cathepsin activity, either in the epidermis (e) or underlying stroma (s).
B: A cervical tumor (t) in a K14-HPV16/E2 transgenic mouse injected with a Our use of a small-molecule inhibitor to pharmacologically
mock solution (PBS) did not have a background autofluorescent signal. knock out protein function has revealed roles for cysteine ca-
C: A K14-HPV16/E2 mouse with high-grade cervical dysplasia (CIN-3) had thepsins during initial angiogenic switching in hyperplastic and
cathepsin activity throughout the underlying stroma (s) below the CIN-3
dysplastic islet progenitor lesions, as well as for tumor growth,lesion (e), both in a punctate manner (arrows) as well as in angiogenic
tumor vascularity, and invasion. The delay in and reduced fre-blood vessels (arrowheads).
D: A similar localization of cathepsin activity was seen in stroma adjacent quency of progression to invasive carcinoma when the cathep-
to the invasive fronds of a cervical carcinoma (t). sin cysteine proteases are inhibited is of particular interest.
E–G: Higher magnification of a dysplastic lesion (E) reveals both cell-associ- Cathepsins have been proposed to function in the initiatingated punctate activity and colocalization with the angiogenic vasculature,
steps of a proteolytic cascade involving serine proteases andas is also the case in tumors (F and G, respectively). The scale bar corre-
sponds to 50 M in A–E and 25 M in F–G. MMPs (reviewed in Koblinski et al., 2000; Rao, 2003). However,
both individual gene knockouts of members of the MMP and
serine protease family (MMP-2, MMP-9 and uPA) and broad-
spectrum MMP inhibition did not affect progression to invasive
cers in the context of sustained estrogen levels (K14-HPV/E2) carcinomas in this model (Bergers et al., 2000). We propose,
via a series of lesional stages analogous to those in humans therefore, that the cathepsins are facilitating the invasive growth
(Arbeit et al., 1996; Elson et al., 2000). The K14-HPV/E2 mice capability, a hallmark of malignancy, through a distinctive path-
evidence a similar angiogenic switch to that observed in RIP1- way. One attractive mechanism would involve proteolysis of
Tag2 mice and in the human cervix (Smith-McCune et al., 1997), E-cadherin, given that loss of E-cadherin function is a determi-
with intense angiogenesis underlying advanced dysplasias (CIN nant of the invasive growth capability in this (Perl et al., 1998)
3) and invasive carcinomas. No cysteine cathepsin activity was and other tumors (Strathdee, 2002; Vleminckx et al., 1991), and
detected in the normal cervix of control female mice (FVB/n/ that extracellular proteolysis has been implicated as one means
E2) following intravenous injection of the fluorescent cysteine to abolish its function (Ito et al., 1999; Rios-Doria et al., 2003);
cathepsin ABP (Figure 8A). In contrast, K14-HPV/E2 mice bear- this possibility is the subject of ongoing investigation.
ing CIN-3 dysplasias or tumors revealed significant levels of Evaluation of the constituent cell types purified from tumors
by flow cytometry (using both quantitative RT-PCR and ABPs)cysteine cathepsin activity. In the CIN-3 lesions, activity was
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revealed that the candidate cathepsin genes were most promi- mor-modulatory responses attributed to the cystatins in other
experimental systems. In any event, the cystatins warrant con-nently expressed in innate immune cell types (granulocytes and
macrophages), as well as in endothelial and tumor cells. Three sideration along with the cathepsins as factors influencing tumor
phenotypes in mouse models and in human cancers.of the six genes were expressed in all three cell fractions, while
cathepsins C and H were selectively expressed by immune In conclusion, with the evidence presented here, perhaps
cysteine cathepsin inhibitors such as JPM-OEt (which showscells, and cathepsin L was preferentially expressed in the tumor
cell compartment. This multiplicity of sources for cathepsin ac- efficacy and no apparent toxicity in the trials performed in this
mouse model), or vinyl sulfone peptidomimetics (e.g., N-methyltivity is provocative: perhaps different cell types are contributing
cathepsins required to manifest distinct functions among the set piperazine-Phe-hPhe-vinyl sulfone phenyl, which is entering
clinical trials for Chagas disease [Engel et al., 1998; McKerrowwe have attributed by their collective pharmacological inhibition.
The prominence of expression of the implicated cathepsin genes et al., 1999]), should be considered for clinical trials treating
cancers known to upregulate these proteases. It is reasonableby innate immune cells adds further weight to the growing con-
sensus that immune infiltrates have the potential to be tumor- to suggest that cathepsin inhibitors may show combinatorial
benefits with other targeted (and traditional) therapies, whichenhancing (Coussens and Werb, 2002). Indeed, we have pre-
viously shown that MMP-9, a matrix metalloprotease, is supplied could be revealed in preclinical trials involving this and other
mouse models of human cancer.exclusively by infiltrating innate immune cells in the RIP1-Tag2
model (Bergers et al., 2000, and our unpublished observations),
Experimental procedureswhere it is principally involved in mobilizing VEGF-A during the
initial angiogenic switch in progenitor lesions (Bergers et al.,
Transgenic mice breeding
2000). Cysteine cathepsins, in contrast, are supplied by multiple The generation of RIP1-Tag2 mice as a model of pancreatic islet cell carcino-
constituent cell types within islet tumors, and have a crucial, genesis has been previously reported (Hanahan, 1985). Similarly, the genera-
nonoverlapping function to that of the MMPs, in facilitating pro- tion of K14-HPV16 transgenic mice (Coussens et al., 1996) and their treat-
ment with 17-estradiol (E2) for cervical carcinogenesis has been reportedgression to the invasive carcinoma stage.
(Arbeit et al., 1996; Elson et al., 2000). Mice were maintained in accordanceTaken together, the data raise important questions for the
with the University of California, San Francisco (UCSF) institutional guidelinesfuture. Which individual cathepsin genes are important for the
governing the care of laboratory mice.
various ascribable functions during tumorigenesis? What cell
type(s) contributes the necessary activity for each of these capa- Microarray and real-time quantitative PCR
bilities? Both cathepsin gene knockout mice and cathepsin sub- Normal (nontransgenic BL/6) and hyperplastic islets (from 5-week-old RIP1-
Tag2 mice) were collected as previously described (Parangi et al., 1995).type-selective inhibitors should provide avenues to address
Angiogenic islets were isolated from 8-week-old RIP1-Tag2 mice by colla-these questions. A broader issue is the prevalence of cathepsin
genase digestion of the excised pancreas, and selected based on their red,upregulation in other types of cancer, a question we have begun
hemorrhagic appearance (Parangi et al., 1995). Tumors were microdissectedto evaluate in another mouse model of cancer, the K14-HPV/E2 from the excised pancreas of 13-week-old RIP1-Tag2 mice and the sur-
model of cervical carcinoma. Interestingly, we observed a similar rounding exocrine tissue carefully removed. RNA was prepared from pools
induction of cysteine cathepsin activity that was not evident in of snap-frozen islets and tumors using an RNeasy kit (Qiagen), DNase
treated, and LiCl precipitated. 10 g of total RNA was used in cDNA synthe-the normal cervix, by using the in vivo ABP. Cathepsin activity
sis, and labeled cRNA subsequently generated using standard protocols.appeared concomitant with the angiogenic switch in the dys-
Microarray hybridizations to the mouse 11K and 19K chips and measurementplastic lesions and was maintained in tumors, much as we had
of hybridization intensities were carried out according to manufacturer’sobserved in the RIP1-Tag2 model. Future functional studies in
protocols (Affymetrix Inc). Each data set was rescaled to normalize for differ-
this and other models should provide insight into the general ences of microarray intensities across the different sets. This scaled data
involvement of cysteine cathepsins in tumor development in was then analyzed using self-organizing map (SOM) (Tamayo et al., 1999)
other organs. analysis to cluster genes with similar expression profiles. Real-time quantita-
tive RT-PCR was performed on cDNA synthesized from normal, angiogenicIf one accepts that our prototypical mouse model may have
islets and tumors, or flow-sorted cells using the 5 nuclease assay (real-timepredictive value for human clinical trials, the lack of apparent
TaqMan RT-PCR) with the ABI PRISM 7700 instrument (ABI) as previouslytoxicity and the demonstrable efficacy of the JPM-OEt inhibitor
described (Elson et al., 2001). Gene-specific primers and probes were de-
when used to target both early and late stages of islet tumorigen- signed for six cathepsins; cathepsin B (forward primer: 5-TTTGATGCACGG
esis are encouraging. Although many human cancers express GAACAATG-3 and reverse primer: 5-TTGGTGTGAATGCAGGTTCG-3,
high levels of cathepsin activity, to date, these proteases have probe: CGGCTCTTGTTGGGCATTTGGG), cathepsin C (forward: 5-AAA
not been prominent drug candidates, likely because of limited TGAGCCTGCGAGATCTGA-3 and reverse: 5-ATTGACGCCTTGGACGT
TTC-3, probe: AAGGATCCCAAGGCCCAAACCTGC), cathepsin H (forward:data implicating them in a direct involvement in tumor progres-
5-GATGTATAAAAGTGGCGTCTACTCCA-3 and reverse: 5-GTTCAATGsion. However, one note of caution when considering pharma-
AGGAAGTACCCATTCTC-3, probe: CCTGGCGGTTGGCTATGGAGAAcological inhibitors of cysteine cathepsins relates to the endoge-
CAG), cathepsin L (forward: 5-AATACAGCAACGGGCAGCA-3 and reverse:
nous inhibitors of cathepsin activity, the cystatins (Turk et al., 5-AGCGGTTCCTGAAAAAGCCT-3, probe: CGCCTTTGGTGACATGACCA
2002). Although their function is broadly antitumorigenic (Kond- ATGAGG), cathepsin S (forward: 5- CGCCAGCCATTCCTCCTT-3, reverse:
uri et al., 2002; Rao, 2003), there have been recent reports 5-ATGATTCACATTGCCCGTACAG-3, probe: ACAAAAGCGGTGTCTATG
ACGACCCC), cathepsin Z (forward: 5-CCTGTCCGGGAGGGAGAA-3 andthat certain cystatins are prometastatic in some experimental
reverse 5-TGGTTGATAACGGCCTGGTC-3, probe: TCCCATCAGCTGCGsystems (Huh et al., 1999; Morita et al., 1999; Utsunomiya et
GGATAATGG).al., 2002), inferring that particular cathepsins could be antimeta-
static. However, there are indications that cystatins have novel
Preparation and labeling of tissue lysates
functions independent of their role as cysteine cathepsin inhi- Normal islets, angiogenic islets, and tumors were collected as above and
bitors (Shridhar et al., 2003). These cathepsin-independent homogenized in lysis buffer (5 mM acetate [pH 5.5], 1 mM EDTA, 2 mM
DTT, 0.1% Triton X-100), and protein concentrations quantitated using thefunctions may, or may not, be contributing to the complex tu-
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